| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2294 |
| Trial ID | NCT04244656 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CTX120 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma |
| Year | 2020 |
| Country | Spain |
| Company sponsor | CRISPR Therapeutics AG |
| Other ID(s) | CRSP-ONC-002 |
| Cohort 1 | |||||||||||
|
|||||||||||